Stacey Cartwright - GlaxoSmithKline PLC Non-Executive Independent Director

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

  Director
Ms. Stacey Cartwright is no longer as NonExecutive Independent Director of Glaxosmithkline Plc effective 31 December 2016. She is a Chartered Accountant and has significant experience of global consumer businesses and of corporate finance. She served as Executive Vice President Chief Financial Officer of Burberry Group plc until July 2013. Prior to joining Burberry Group plc in 2004 Stacey held the role of Chief Financial Officer at Egg plc between 1999 and 2003 and from 1988 to 1999 she worked in various financerelated positions at Granada Group plc. The Board has determined that Stacey has recent and relevant financial experience and agreed that she has the appropriate qualifications and background to be an audit committee financial expert.
Age: 51  Director Since 2011      
(44) 20 8047 7807  www.gsk.com

Stacey Cartwright Latest Insider Activity

GlaxoSmithKline PLC Management Efficiency

GlaxoSmithKline PLC has Return on Asset of 7.0E-4 % which means that on every $100 spent on asset it made $7.0E-4 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 1.0E-4 % implying that it generated $1.0E-4 on every 100 dollars invested. GlaxoSmithKline PLC management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. GlaxoSmithKline PLC Return on Investment is decreasing as compared to previous years. The last year's value of Return on Investment was reported at 18.28. The current Return on Invested Capital is estimated to increase to 0.18, while Return on Average Assets are estimated to decrease to 0.0007. GlaxoSmithKline PLC Tangible Asset Value is increasing as compared to previous years. The last year's Tangible Asset Value was reported at 38.17 Billion. The current Total Liabilities is estimated to decrease to about 57 B. The current Current Liabilities is estimated to decrease to about 13.4 B
The company has 36.63 B in debt with debt to equity (D/E) ratio of 182.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. GlaxoSmithKline PLC has Current Ratio of 0.8 suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Belen MorenesGrifols S A
2013
Christopher ToveyGW Pharmaceuticals Plc
2012
Kelly KramerGilead Sciences
2016
Robert KidderMerck Company
2005
Mateo HumbertGrifols S A
2014
Antonio ParesGrifols S A
2014
Mary BeckerleJohnson Johnson
2015
Marc DunoyerAstrazeneca PLC
2013
Jacqueline BartonGilead Sciences
2018
Stephen WrightGW Pharmaceuticals Plc
2005
Kathi SeifertEli Lilly And
1995
Ronald WilliamsJohnson Johnson
2011
Luis BobadillaGrifols S A
2011
Ralph AlvarezEli Lilly And
2009
Katherine BaickerEli Lilly And
2011
JeanPhilippe CourtoisAstrazeneca PLC
2008
Paul RothmanMerck Company
2015
Graham ChipchaseAstrazeneca PLC
2019
Anne MulcahyJohnson Johnson
2012
Per WoldOlsenGilead Sciences
2010
William WaldegraveGW Pharmaceuticals Plc
2017

Company Summary

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 99437 people.GlaxoSmithKline PLC (GSK) is traded on BATS Exchange in USA. It is located in 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom and employs 99,437 people. GlaxoSmithKline PLC is listed under Pharmaceutical Products category by Fama And French industry classification.

GlaxoSmithKline PLC Leadership Team

Vindi Banga, Senior Independent Non-Executive Director
Lynn Elsenhans, Independent Non-Executive Director
Luke Miels, President - Global Pharmaceuticals
Hal Barron, Chief Scientific Officer, President - Research & Development, Executive Director
Daniel Podolsky, Non-Executive Independent Director
Emma Walmsley, Chief Executive Officer, Executive Director
Luc Debruyne, President - Global Vaccines
Andrew Witty, CEO, Executive Director
Brian McNamara, Chief Executive Officer - GSK Consumer Healthcare
Charles Bancroft, Non-Executive Director
Roy Anderson, Non-Executive Independent Director
Philip Hampton, Independent Non-Executive Director
Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Vivienne Cox, Non-Executive Independent Director
Bill Louv, Senior Vice President - Core Business Services
Diana Conrad, Senior Vice President - Human Resources
Roger Connor, President - Global Manufacturing & Supply
Abbas Hussain, President Global Pharmaceuticals
Phil Thomson, Senior Vice President - Global Communications
Judy Lewent, Non-Executive Independent Director
Hans Wijers, Independent Non-Executive Director
Stephanie Burns, Non-Executive Independent Director
Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Urs Rohner, Non-Executive Independent Director
Marvinder Banga, Senior Non-Executive Independent Director
Deryck Maughan, Senior Independent Non-Executive Director
Jesse Goodman, Non-Executive Independent Director
Laurie Glimcher, Non-Executive Independent Director
Nick Hirons, Senior Vice President - Global Ethics and Compliance
Sally Jackson, Senior Vice President - Global Communications and CEO Office
James Ford, Senior Vice President General Counsel
Victoria Whyte, Company Secretary
Daniel Troy, Sr. VP and General Counsel
Shah Hussain, President - Europe, Japan & EMAP
Manvinder Banga, Non-Executive Director
David Redfern, Chief Strategy Officer
Patrick Vallance, President - Pharmaceuticals R&D
Stacey Cartwright, Non-Executive Independent Director
Regis Simard, President - Pharmaceutical Supply Chain
Jonathan Symonds, Independent Non-Executive Chairman of the Board
Iain Mackay, Chief Financial Officer, Executive Director
Karenann Terrell, Chief Digital & Technology Officer
Deborah Waterhouse, Chief Executive Officer - ViiV Healthcare
Claire Thomas, Senior Vice President - Human Resources

Stock Performance Indicators

Did you try this?

Run Cryptocurrency Center Now

   

Cryptocurrency Center

Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page